Label

North America Smoking Cessation and Nicotine De-Addiction Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 07-Jan-2020 | No of Pages: 80

Price



USD 3995
USD 5795
DM ID :

Publish Date:

07-Jan-2020

Total pages:

80

North America smoking cessation and nicotine de-addiction market is projected to register 23.9% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:
Smoking cessation is a mechanism that can avoid the smoking habits. The cycle reduces the risk of cancer and other serious health issues. The treatment includes occupational intervention, counselling, medications and items containing cigarettes, lozenges, tobacco, patches of cigarettes, inhalers and sprays. Stopping smoking is sometimes very hard to break, because it depends upon the psychological and physical dependency of both the cigarette and the habit of the person.
Some of the major factors contributing to the growth of the North America smoking cessation and nicotine de-addiction market:

• Consumption of e-cigarettes and other nicotine products has been increased substantially
• Increasing the awareness about the health impacts of smoking.

Market Players:
The key players of North America smoking cessation and nicotine de-addiction market are:
• Imperial Brands
• 22nd Century Group, Inc
• Pfizer Inc.
• Dr. Reddy’s Laboratories Ltd
• Glaxosmithkline Plc.
• British American Tobacco
• Cambrex Corporation
• Cipla Inc.
• Fertin Pharma
• Johnson & Johnson Services, Inc.
• Perrigo Company Plc

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.